THERAPEUTIC USES
OF STEROID HORMONES
Adrenal insufficiency may
result from hypofunction of the adrenal cortex (primary adrenal insufficiency,
Addison’s disease) or from a malfunctioning of the hypothalamic–pituitary
system (secondary adrenal in-sufficiency). In treating primary adrenal insufficiency,
one should administer sufficient cortisol to diminish hy-perpigmentation and
abolish postural hypotension; these are the cardinal signs of Addison’s
disease.
Although patients may require
varying amounts of replacement steroid, 20 to 30 mg/day of cortisol
supple-mented with the mineralocorticoid 9- -fluorocortisol (0.1 mg/day) is
generally adequate. A doubling of the cortisol dose may be required during
minor stresses or infections. In patients who require high-dose
supple-mentation, prednisone can be substituted for cortisol to avoid fluid
retention.
In the treatment of secondary
adrenocortical insuf-ficiency, lower doses of cortisol are generally effective,
and fluid and electrolyte disturbances do not have to be considered, since
patients with deficient corticotrophin secretion generally do not have abnormal
function of the zona glomerulosa. Since cortisol replacement ther-apy is
required for life, adequate assessment of patients is critical to avoid the
serious long-term consequences of excessive or insufficient treatment. In many
cases, the doses of glucocorticoid used in replacement therapy are probably too
high. Patients should ideally be adminis-tered three or more doses daily. To
limit the risk of osteoporosis, replacement therapy should be carefully
assessed on an individual basis and overtreatment avoided.
Since glucocorticoids possess
a wide range of effects on virtually every phase and component of the
inflamma-tory and immune responses, they have assumed a major role in the
treatment of a wide spectrum of diseases with an inflammatory or
immune-mediated component. Rheumatoid arthritis is the original condition for
which antiinflammatory steroids were used, and they remain a mainstay of
therapy. Intraarticular glucocorticoid injec-tions have proven to be
efficacious, particularly in chil-dren. However, the detrimental effects of
glucocorti-coids on growth are significant for children with active arthritis.
Although steroids offer symptomatic relief from this disorder by abolishing the
swelling, redness, pain, and effusions, they do not cure. Progressive deteri-oration
of joint structures continues, and the disease process may be exacerbated after
steroid therapy is ter-minated .
Based on the concept that
asthma is an inflamma-tory disease that leads to airway obstruction, inhaled
glucocorticoids are the first-line treatment for moderate to severe asthma.
Inhaled preparations are particularly effective when used to prevent recurrent
attacks. This therapy is often combined with an inhaled bron-chodilator such as
a β-adrenergic agonist. The use
of β-adrenergic agonists or
theophylline enables use of a lower dose of glucocorticoid, especially in
patients rela-tively resistant to therapy .
Steroids are used in other
collagen diseases, such as lupus erythematosus; in hypersensitivity or allergic
states, such as nephrotic syndrome, ulcerative colitis, and Crohn’s disease; in
granulomatous disease, such as sarcoid; and in a wide range of dermatological
and ophthalmological conditions. Glucocorticoids may also be used at lower
doses in combination with other drugs for the treatment of vasculitis, lupus
nephritis, and amyloidosis. Steroids are valuable in the prevention and
treatment of organ transplant rejec-tion and in the improvement of muscle
function in polymyositis.
Corticosteroids are the
mainstay of therapy for in-flammatory demyelinating polyneuropathies. In
Guillain-Barré syndrome glucocorticoids reduce the inflamma-tory attack and
improve final outcome, while in chronic inflammatory demyelinating
polyneuropathy glucocor-ticoids suppress the immune reaction but may not
re-tard the progression of the disease. Glucocorticoids also exert a
facilitatory action on neuromuscular transmis-sion that may contribute to their
efficacy in certain neu-romuscular disorders. The fact that acetylcholine
recep-tor antibodies are responsible for the neuromuscular transmission defect
in myasthenia gravis has provided a rationale for exploiting the
immunosuppressive effects of glucocorticoids .
Although infections are
generally thought to be particularly frequent and possibly severe in patients
treated with steroids, they have been used as short-term adjunctive therapy to
reduce the severe symptoms asso-ciated with such bacterial infections as acute H. influen-zae and miliary tuberculosis
and in viral infections, such as
hepatitis and infectious mononucleosis.
Glucocorticoids are also used
in the treatment of a number of HIV-related disorders, including Pneumo-cystis carinii pneumonia,
demyelinating peripheral neu-ropathies, tuberculous meningitis, and
nephropathy. Glucocorticoids are used as adjunctive therapy in Pneumo cystitis
carinii pneumonia to decrease the in-flammatory response and allow time for
antimicrobial agents to exert their effects. In patients who are
im-munocompromised because of HIV infection, adjunctive steroids may be less
beneficial in promoting survival.
Steroids are important
components in the treatment of hematopoietic malignancies. Their efficacy in
chronic lymphocytic leukemia and multiple myeloma stems from their lympholytic
effects to reduce cell prolifera-tion, promote cell cycle arrest, and induce
cell death by apoptosis. A complication of chronic lymphocytic leukemia, that
is, autoimmune hemolytic anemia, also responds favorably to steroids. However,
the develop-ment of resistance may limit the effectiveness of steroid therapy.
Prompt intensive treatment
with corticosteroids may be lifesaving when an excessive inflammatory reaction
has resulted in septic shock. A massive infusion of cortico-steroids can
restore cardiac output and reverse hy-potension by sensitizing the response of
adrenoceptors in the heart and blood vessels to the stimulating action of
catecholamines. This protective role of steroids may be due to a direct effect
on vascular smooth muscle. The combination of glucocorticoids and dopamine
therapy preserves renal blood flow during shock.
Congenital enzymatic defects
in the adrenal biosyn-thetic pathways lead to diminished cortisol and
aldo-sterone production and release. In these conditions, corticotrophin
secretion is increased, and adrenal hy-perplasia occurs, accompanied by
enhanced secretion of steroid intermediates, especially adrenal androgens. More
than 90% of cases of congenital adrenal hyper-plasia are due to 21-hydroxylase
deficiency, which is cre-ated by mutations in the CYP21 gene encoding the
en-zyme. Overproduction of androgens causes virilization, accelerated growth,
and early epiphysial fusion. Treat-ment of this condition requires
administration of gluco-corticoid in amounts adequate to suppress adrenal
an-drogen secretion but insufficient to compromise bone growth and
mineralization. Approximately 75% of pa-tients have concomitant
mineralocorticoid deficiency and therefore cannot synthesize sufficient
aldosterone to maintain sodium balance. These patients may de-velop potentially
fatal salt-wasting if not treated.
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2023 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.